Mounjaro® (Tirzepatide) is an FDA-approved, dual GIP/GLP-1 receptor agonist that targets Type 2 Diabetes (T2D) with a focus on glycemic and weight management. Clinical studies, including SURPASS-4, showcased significant HbA1c reductions and weight loss, as well as a lower mortality rate than insulin glargine. It’s well-tolerated with a safety profile similar to GLP-1 agonists, making it an advanced option for T2D. This novel therapy may also benefit obesity and other metabolic conditions, setting a new standard in dual-acting diabetes treatments with broad future applications.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Tirzepatide by Unlabelled, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
